AavantiBio
747 SW 2nd Ave, IMB31
Riverview II, 18th Floor
Gainesville
FL
32601
United States
Website: http://www.aavantibio.com/
8 articles about AavantiBio
-
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
12/5/2022
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its acquisition of AavantiBio, a privately held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, including its pipeline assets and net cash.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Solid Biosciences and AavantiBio – announced Friday they are merging to develop a portfolio of neuromuscular and cardiac programs, initially focusing on Duchenne muscular dystrophy.
-
AavantiBio Announces Formation of Scientific Advisory Board
2/9/2022
AavantiBio today announced the formation of its Scientific Advisory Board (SAB) and its members.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
AavantiBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.
-
AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer
11/16/2021
-
It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.